Oliva, M., Cabezas-Camarero, S., Olivares-Hernández, A., Chaves, M., Medina-Colmenero, A., Llop-Serna, S., Arrazubi, V., Flor, M. J., Munoz-Unceta, N., Ceballos, I., Docampo, L. I., Serrano, G., Durán, M., Montalbán, C., Pérez-Segura, P., Mesia, R., Baste, N. (2026). ERBIOTAX (TTCC-2022-02): A phase II, multicenter, randomized study of cetuximab with or without weekly paclitaxel after progression on first-line pembrolizumab plus platinum/5-FU in recurrent or metastatic head and neck squamous cell carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps6131